Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma

Ahmed I Foudah1, Mohammed H Alqarni1, Tariq M Aljarba1

  • 1Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942, Al Kharj, Saudi Arabia.

Molecular Diversity
|September 10, 2025
PubMed

Insights

Researchers identified a novel compound, 153295720, as a potent inhibitor of Cyclin-dependent kinase 20 (CDK20). This discovery offers a promising strategy for targeting hepatocellular carcinoma (HCC) by stabilizing key CDK20 residues.

Area of Science:

  • Oncology
  • Biochemistry
  • Computational Chemistry

Background:

  • Cyclin-dependent kinase 20 (CDK20/CCRK) is implicated in hepatocellular carcinoma (HCC) progression.
  • CDK20 regulates beta-catenin signaling and cell proliferation in HCC.
  • Selective small-molecule inhibitors for CDK20 are currently lacking.

Purpose of the Study:

  • To identify novel small-molecule inhibitors of CDK20.
  • To computationally screen and validate potential CDK20 inhibitors.
  • To provide a basis for experimental targeting of CDK20 in HCC.

Main Methods:

  • Virtual screening of PubChem database for compounds similar to a known CDK20 inhibitor.
  • Structure-based virtual screening using MTiOpenScreen and docking against AlphaFold-predicted CDK20.
  • Geometry optimization via density functional theory (B3LYP/cc-pVDZ).
  • Molecular dynamics (MD) simulations (500 ns) and MM/GBSA binding energy calculations.
  • Free energy landscape analysis.

Main Results:

  • Compound 153295720 demonstrated the highest binding affinity (-11.8 kcal/mol) to CDK20.
  • 153295720 formed key interactions with active-site residues Met84, Lys33, Ala131, and Asp145.
  • MD simulations confirmed the stability of the 153295720-CDK20 complex, with minimal fluctuations.
  • MM/GBSA analysis yielded the most favorable binding energy (-69.09 ± 8.29 kcal/mol) for 153295720.
  • The reference compound showed greater conformational drift compared to 153295720.

Conclusions:

  • Compound 153295720 is a structurally and dynamically superior CDK20 inhibitor.
  • This inhibitor effectively stabilizes critical catalytic residues of CDK20.
  • Findings support the potential of 153295720 for HCC treatment and guide future experimental validation.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K